Renhe PharmacyLtd Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Renhe PharmacyLtd has been growing earnings at an average annual rate of 0.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 2.8% per year. Renhe PharmacyLtd's return on equity is 7.2%, and it has net margins of 10.1%.
Información clave
0.8%
Tasa de crecimiento de los beneficios
-1.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 10.9% |
| Tasa de crecimiento de los ingresos | 2.8% |
| Rentabilidad financiera | 7.2% |
| Margen neto | 10.1% |
| Última actualización de beneficios | 30 Sep 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Renhe PharmacyLtd. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 24 | 4,364 | 443 | 745 | 40 |
| 30 Jun 24 | 4,715 | 548 | 764 | 42 |
| 31 Mar 24 | 4,914 | 562 | 833 | 45 |
| 31 Dec 23 | 5,032 | 567 | 809 | 46 |
| 30 Sep 23 | 5,126 | 658 | 882 | 40 |
| 30 Jun 23 | 5,274 | 631 | 891 | 43 |
| 31 Mar 23 | 5,198 | 601 | 877 | 44 |
| 01 Jan 23 | 5,153 | 574 | 871 | 51 |
| 30 Sep 22 | 5,122 | 597 | 874 | 49 |
| 30 Jun 22 | 5,140 | 634 | 870 | 52 |
| 31 Mar 22 | 5,029 | 668 | 836 | 55 |
| 01 Jan 22 | 4,936 | 665 | 852 | 52 |
| 30 Sep 21 | 4,864 | 725 | 742 | 56 |
| 30 Jun 21 | 4,687 | 669 | 802 | 47 |
| 31 Mar 21 | 4,614 | 630 | 831 | 43 |
| 31 Dec 20 | 4,278 | 580 | 801 | 40 |
| 30 Sep 20 | 4,100 | 478 | 924 | 39 |
| 30 Jun 20 | 4,078 | 456 | 937 | 41 |
| 31 Mar 20 | 4,273 | 498 | 995 | 37 |
| 31 Dec 19 | 4,581 | 538 | 1,065 | 38 |
| 30 Sep 19 | 4,622 | 553 | 1,062 | 32 |
| 30 Jun 19 | 4,590 | 586 | 1,025 | 49 |
| 31 Mar 19 | 4,549 | 543 | 1,068 | 35 |
| 31 Dec 18 | 4,403 | 506 | 1,061 | 31 |
| 30 Sep 18 | 4,465 | 515 | 1,107 | 31 |
| 30 Jun 18 | 4,321 | 463 | 1,085 | 23 |
| 31 Mar 18 | 4,059 | 407 | 984 | 29 |
| 31 Dec 17 | 3,844 | 380 | 896 | 23 |
| 30 Sep 17 | 3,679 | 360 | 822 | 17 |
| 30 Jun 17 | 3,611 | 357 | 800 | 0 |
| 31 Mar 17 | 3,557 | 348 | 759 | 0 |
| 31 Dec 16 | 3,567 | 372 | 731 | 0 |
| 30 Sep 16 | 3,324 | 397 | 655 | 0 |
| 30 Jun 16 | 3,099 | 403 | 620 | 0 |
| 31 Mar 16 | 2,858 | 421 | 593 | 0 |
| 31 Dec 15 | 2,524 | 391 | 542 | 0 |
| 30 Sep 15 | 2,451 | 366 | 588 | 0 |
| 30 Jun 15 | 2,411 | 341 | 607 | 0 |
| 31 Mar 15 | 2,346 | 322 | 609 | 0 |
| 31 Dec 14 | 2,253 | 301 | 598 | 0 |
| 30 Sep 14 | 2,114 | 213 | 612 | 0 |
| 30 Jun 14 | 1,949 | 169 | 568 | 0 |
| 31 Mar 14 | 1,812 | 173 | 523 | 0 |
| 31 Dec 13 | 1,799 | 194 | 514 | 0 |
Ingresos de calidad: 000650 has high quality earnings.
Margen de beneficios creciente: 000650's current net profit margins (10.1%) are lower than last year (12.8%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 000650's earnings have grown by 0.8% per year over the past 5 years.
Acelerando crecimiento: 000650's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Beneficios vs. Industria: 000650 had negative earnings growth (-32.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rentabilidad financiera
Alta ROE: 000650's Return on Equity (7.2%) is considered low.